NV-AQARA
8.1.2024 18:01:32 CET | Business Wire | Press release
Aqara, a leading provider of smart home products, is thrilled to announce its participation in CES 2024. At the event, Aqara will showcase its latest innovations, including the new Border Router Plug and Smart Lock U300, as well as other advanced smart home solutions and prototypes at its booth in the Venetian Expo (#53513).
Aqara is an early advocate of the industry-unifying Matter standard and is committed to delivering seamless smart home experiences for users. The Border Router Plug and Smart Lock U300 will be Thread-capable, which will add to Aqara's growing number of native Matter products, making Aqara devices more interoperable. These two new products previewed at CES are expected to become available for order in the coming months.
Border Router Plug
The Aqara Border Router Plug represents an innovative advancement in smart plug and is among the first smart plugs announced to incorporate Thread Border Router capabilities. Equipped with Thread and dual-band Wi-Fi, this plug enables Matter controllers without Thread capability to manage Thread devices, allowing seamless integration of Thread devices into smart home systems without needing a new Matter controller.
This plug is energy-efficient, particularly in Thread-only mode, which reduces idle consumption while extending the mesh Thread network by routing the data packets. It is also energy-conscious, providing real-time and historical data on home energy consumption, enabling users to automate their electrical devices to reduce energy waste. Additionally, the Border Router Plug can sense the on/off status of the connected appliance and trigger Aqara Home automations accordingly. For example, users can have the curtains close automatically when the TV is on to eliminate potential sun glare.
The Aqara Border Router Plug utilizes an NXP® Semiconductors' secure wireless MCU. As part of the ongoing collaboration between Aqara and NXP Semiconductors, the Border Router Plug will also be featured in NXP's Smart Home Experience showcase during CES 2024, along with the NXP-powered Aqara Door and Window Sensor P2.
Smart Lock U300
The Aqara Smart Lock U300 is one of the first smart lever locks announced to feature Matter and Thread compatibility, and offers unprecedented interoperability with various smart home platforms. This versatility is coupled with an extended battery life of up to 8 months and enhanced local control, which improves responsiveness, privacy and security.
Designed for both indoor and outdoor use, the U300 replaces the traditional US lever or knob on single-bore doors and is ideal for including side entries, garage entries, home offices, basements and storage rooms. It enables a key-free lifestyle with multiple access options, including fingerprints, PIN codes, NFC, or voice assistants. Homeowners can control the lock remotely, grant temporary access to guests, and receive real-time notifications of who comes and goes - all from a smartphone.
Aqara Home App Update
At CES 2024, Aqara will also showcase Home Copilot, the new chatbot interface for the Aqara Home app, which is powered by Gen-AI. Home Copilot is designed to enhance user experiences by utilizing ambient intelligence, which helps convert real-time data and insights into actions. Ultimately, Home Copilot will be able to analyze the usage patterns in an Aqara home and proactively suggest customized automations. It will also understand natural language and configure automations per user requests. Users can automate their homes via simple voice and text instructions, which makes smart home even more intuitive and easy to use.
Initially, Home Copilot will enable Aqara Insights, a daily, weekly and monthly smart home reports for users, and provide tailored plans for energy-saving automation. It will support natural language queries for Aqara devices and automations and offer proactive assistance with device setup and troubleshooting. Home Copilot will also spearhead the AI-powered customer support interface for Aqara users in over 10 languages.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240108777203/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom